Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00121680
Status:
COMPLETED
Last Update Posted:
2015-12-11
First Post:
2005-07-15
Brief Title:
A Phase IIb Multicenter Open-Label Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced andor Metastatic Melanoma
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
A Phase IIb Multicenter Open-Label Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced andor Metastatic Melanoma
Status:
COMPLETED
Status Verified Date:
2015-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to study the safety of E7080 administered to patients with solid tumors or lymphomas
Please note this study is now recruiting patients with advanced andor metastatic melanoma only
In the current phase of this study To determine the MTD and the pharmacokinetic profile of E7080 when given as continuous daily qd dosing in combination with temozolomide
Please note this study is now recruiting patients with advanced andor metastatic melanoma only
In the current phase of this study To determine the MTD and the pharmacokinetic profile of E7080 when given as continuous daily qd dosing in combination with temozolomide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None